Patents Examined by Andrea K McCollum
  • Patent number: 11111293
    Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: September 7, 2021
    Assignee: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Patent number: 11110176
    Abstract: Embodiments of the disclosure pertain to compositions containing (i) one or more non-antifreeze proteins or cell components or cells and (ii) one or more antifreeze proteins (AFPs), mimetics thereof, and/or analogs thereof, and a method of stabilizing a biologic (e.g., a protein, microbe, cell component or cell) against temperature stress and aggregation. The AFP may be selected from known antifreeze polypeptides and antifreeze peptides, analogs and mimetics of antifreeze proteins, active fragments of such antifreeze proteins, polypeptide and peptide mimetics, antifreeze peptoids and polymers, and combinations thereof. The non-antifreeze protein, cell component or cell comprises a known protein, cell component or cell used in the pharmaceutical, medical, agricultural, veterinary and/or food industry(ies). The AFP protects the function of the non-antifreeze protein, microbe(s), cell component(s) or cell(s) under temperature stress (e.g., a temperature of ?20-60° C.).
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 7, 2021
    Assignee: The Board of Trustees of the California State University
    Inventor: Xin Wen
  • Patent number: 11111313
    Abstract: The present disclosure provides monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), which can block the binding of PCSK9 to low-density lipoprotein (LDL) receptor, and therefore lower the level low-density lipoprotein cholesterol (LDL-C). The antibodies of disclosure provide very potent agents for the treatment of multiple Cardiovascular diseases (CVDs).
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: September 7, 2021
    Assignee: WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Jieying Liu, Jing Li
  • Patent number: 11091525
    Abstract: Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: August 17, 2021
    Assignee: Nektar Therapeutics
    Inventors: Jicai Huang, Yujun Wang
  • Patent number: 11091540
    Abstract: Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: August 17, 2021
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
  • Patent number: 11091523
    Abstract: Recombinant transforming growth factor (TGF)-? monomers modified to inhibit dimerization and block TGF-? signaling are described. The recombinant TGF-? monomers lack the ability to bind and recruit TGF-? type I receptor (T?RI), but retain the capacity to bind the high affinity TGF-? type II receptor (T?RII), and in some instances, include mutations that increase their affinity for T?RII. Nucleic acid molecules and vectors encoding the recombinant TGF-? monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-? monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-? monomers and/or cells producing the recombinant TGF-? monomers, to inhibit TGF-? signaling, such as to treat disorders associated with aberrant TGF-? signaling, are also described.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 17, 2021
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Research Council of Canada
    Inventors: Andrew Peterson Hinck, Traian Sulea
  • Patent number: 11083778
    Abstract: Methods and compositions for preventing an immune response to an immunogenic therapeutic agent [i.e. anti-drug antibody (ADA), a.k.a. anti-therapeutic antibody (ATA)] are disclosed. One of the disclosed methods comprises administering an effective amount of an immunosuppressant such as an Interleukin-2 (IL-2) signaling pathway inhibitor, including an antagonist, super agonist or partial agonist to the cytokine IL-2, to the IL-2 receptor (IL-2R), or to IL-2R signal transduction molecules. Inhibitors can be in the form of antibodies or antibody fragments, peptide inhibitors, fusion molecule, small molecules, antibody/small molecule conjugates. Administration of a given inhibitor can decrease the incidence and/or magnitude of an immune response or prevent an immune response, including an antibody response, to a potentially immunogenic therapeutic agent in a non-human primate (NHP). Some of the disclosed methods produce a tolerizing effect in NHPs.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 10, 2021
    Assignee: JOMOCO, Corp
    Inventor: Jack A. Ragheb
  • Patent number: 11059895
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: July 13, 2021
    Assignee: Amgen Inc.
    Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
  • Patent number: 11046752
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: June 29, 2021
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Quinn Deveraux
  • Patent number: 11028149
    Abstract: Provided is a method capable of producing a protein at a high level using a cultured animal cell, comprising culturing a cell that expresses APES (Antibody Production Enhancing Sequence) and into which a DNA encoding a desired polypeptide has been introduced, thereby producing the desired polypeptide. APES contains a nucleotide sequence related to nuclear factor ?B inhibitor ? (NfkBia) and has a function of decreasing the intracellular expression of NfkBia.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: June 8, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hisahiro Tabuchi, Tomoya Sugiyama
  • Patent number: 10994157
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: May 4, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Patent number: 10987399
    Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: April 27, 2021
    Assignee: XERIS PHARMACEUTICALS, INC.
    Inventors: Steven Prestrelski, John Kinzell
  • Patent number: 10968271
    Abstract: The present invention relates to amino acid sequences that are directed against Interleukin-23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODIES® against IL-23 and one NANOBODY® against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: April 6, 2021
    Assignee: Ablynx N.V.
    Inventor: Marie-Ange Buyse
  • Patent number: 10960079
    Abstract: Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 30, 2021
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Cherie F. Ali, Xiaofeng Liu, Deborah H. Charych, Yujun Wang
  • Patent number: 10947303
    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 16, 2021
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD.
    Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
  • Patent number: 10899816
    Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: January 26, 2021
    Assignees: INSERM (Institut National De La Santé Et De La Recherche Medicale), Cytune Pharma
    Inventors: Sebastien Daniel Morisseau, Geraldine Teppaz, Yannick Laurent Joseph Jacques, Bruno Gilbert Marc Robert, Guy Luc Michel De Martynoff, David Bechard
  • Patent number: 10884001
    Abstract: Featured are methods of diagnosing and treating liver disease.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 5, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Detlef Schuppan, Towia Libermann, Simon T. Dillon, Yury Papou
  • Patent number: 10870690
    Abstract: The present invention relates to compositions for treating cancer by having one or more activities of inhibiting cancer growth, inhibiting cancer cell invasion, and inhibiting cancer recurrence.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: December 22, 2020
    Inventor: Yihong Zhou
  • Patent number: 10858452
    Abstract: The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: December 8, 2020
    Assignees: Insitut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, Universite d'Angers, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Nantes
    Inventors: Erwan Mortier, Dihia Meghnem, Sebastien Morisseau, Yannick Jacques
  • Patent number: 10858447
    Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to Proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity, also provides a nucleic acid molecule encoding the antibody of the invention or the functional fragment thereof, for expressing an expression vector and a host cell of the antibody or the functional fragment thereof, and also provides a method for producing the antibody or the functional fragment thereof. The present invention provides that the antibody or the functional fragment thereof is used for treating diseases such as dyslipidemia.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: December 8, 2020
    Assignees: Junshi Biosciences Co., Ltd., Junmeng Biosciences Co., Ltd.
    Inventors: Hai Wu, Bo Chen, Hui Feng, Sheng Yao, Jian Yao, Hongchuan Liu, Libo Zhang, Jing Zhang, Dan Meng